Aprea Therapeutics prices $5.5M public offering of 1.05M shares at $5.25/share

Aprea Therapeutics, Inc.

Gross proceeds ~$5.5M from 1,050,000 shares at $5.25/share; net proceeds ~$4.8M after discounts and expenses.
Underwriters granted 30-day option to purchase up to 157,500 additional shares.
Proceeds to fund clinical asset ATRN-119, pre-clinical ATRN-W1051, and general corporate purposes.
Offering expected to close Feb 27, 2023; Maxim Group LLC sole book-runner.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aprea Therapeutics, Inc. entered into Underwriting Agreement with Maxim Group LLC valued at approximately $4.8 million (effective 2023-02-22).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Value: approximately $4.8 million
Effective: 2023-02-22

Exact text from the filing

On February 22, 2023, Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC as representative of the underwriters named therein (the “Underwriters”) relating to the issuance and sale of 1,050,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-025392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.